[Pro- and antiatherogenic mechanisms in chronic kidney failure]

Likars'Ka Sprava
|April 16, 1999
PubMed

Insights

Atherosclerosis accelerates in chronic renal insufficiency (ChRI) patients due to specific proatherogenic and antiatherogenic factors. Further research is needed to understand ChRI pathogenesis for better prevention and treatment.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Pathophysiology

Context:

  • Atherosclerosis is a major cause of mortality in patients with chronic renal insufficiency (ChRI).
  • Understanding the mechanisms driving accelerated atherosclerosis in ChRI is crucial for patient outcomes.
  • Patients with manifest and terminal ChRI, undergoing various renal replacement therapies, are the focus.

Purpose:

  • To review current knowledge on the causes of rapidly advancing atherosclerosis in chronic renal insufficiency.
  • To discuss both generally known and ChRI-specific proatherogenic mechanisms.
  • To explore antiatherogenic mechanisms relevant to chronic renal insufficiency.

Summary:

  • This review examines the complex interplay of factors contributing to accelerated atherosclerosis in chronic renal insufficiency (ChRI).
  • It details proatherogenic influences, including those unique to ChRI, and counteracting antiatherogenic mechanisms.
  • The article synthesizes current understanding of atherosclerosis development in patients on conservative treatment, hemodialysis, or peritoneal dialysis.

Impact:

  • Highlights the need for targeted research into ChRI pathogenesis.
  • Suggests avenues for developing novel preventive and therapeutic strategies for atherosclerosis in renal insufficiency.
  • Aims to improve clinical management and reduce mortality associated with cardiovascular complications in ChRI patients.

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...